title: Cross Talk between Wnt/β-Catenin and CIP2A/Plk1 Signaling in Prostate Cancer: Promising Therapeutic Implications.
abstract: Aberrant activation of the Wnt/β-catenin pathway and polo-like kinase 1 (Plk1) overexpression represent two common events in prostate cancer with relevant functional implications. This minireview analyzes their potential therapeutic significance in prostate cancer based on their role as androgen receptor (AR) signaling regulators and the pivotal role of the tumor suppressor protein phosphatase 2A (PP2A) modulating these pathways.
authors.affiliation: Translational Oncology Division, Oncohealth Institute, IIS Fundación Jiménez Diaz, UAM, University Hospital Fundación Jiménez Diaz, Madrid, Spain ion.cristobal@fjd.es jgfoncillas@gmail.com.
authors.forename: Ion
authors.initials: I
authors.lastname: Cristóbal
authors.affiliation: Pathology Department, IIS Fundación Jiménez Diaz, UAM, Madrid, Spain.
authors.forename: Federico
authors.initials: F
authors.lastname: Rojo
authors.affiliation: Pathology Department, IIS Fundación Jiménez Diaz, UAM, Madrid, Spain.
authors.forename: Juan
authors.initials: J
authors.lastname: Madoz-Gúrpide
authors.affiliation: Translational Oncology Division, Oncohealth Institute, IIS Fundación Jiménez Diaz, UAM, University Hospital Fundación Jiménez Diaz, Madrid, Spain ion.cristobal@fjd.es jgfoncillas@gmail.com.
authors.forename: Jesús
authors.initials: J
authors.lastname: García-Foncillas
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001324:Autoantigens / Q000378:metabolism*; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D004359:Drug Therapy, Combination; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D047908:Intracellular Signaling Peptides and Proteins; D008297:Male; D008565:Membrane Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D011518:Proto-Oncogene Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects; D060449:Wnt Signaling Pathway / Q000187:drug effects; D000097869:Polo-Like Kinase 1
chemical_list: D000970:Antineoplastic Agents; D001324:Autoantigens; D018797:Cell Cycle Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008565:Membrane Proteins; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D000097869:Polo-Like Kinase 1; C500266:CIP2A protein, human